Back to top

Tale of the Tape

Zacks Equity Research

Investors are Betting Against Sarepta Therapeutics Inc. (SRPT) Should You?
September 26, 2013


Trades from $3
Many investors appear to be quite bearish Sarepta Therapeutics Inc. (SRPT - Free Report) especially if you look at the percentage of the float that is sold short for this stock. Currently, 39.9% of the float is sold short, suggesting an extreme level of bearishness for SRPT.

However, it is worth noting that earnings estimates have actually been moving higher for the company, despite the pessimism. Thanks to these rising estimates, we actually have a Zacks Rank #2 (Buy) on SRPT, so we clearly don’t believe in the negativity surrounding this firm, and are instead looking for shares of SRPT to move higher in the weeks ahead.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Sarepta Therapeutics, Inc. (SRPT) - free report >>